GLPwatch
Trulicity for Heart failure (HFpEF)
dulaglutide · Investigational / off-label
Last updated 2026-05-28 15:46 UTCTrulicity (dulaglutide) is not FDA-approved for treating heart failure with preserved ejection fraction (HFpEF), and any use for this condition is off-label or investigational. Research includes preclinical and observational studies suggesting potential benefits, but these do not establish efficacy for FDA-approved use.
AI summary of the sources below.
| Drug | Trulicity (dulaglutide) |
|---|---|
| Condition | Heart failure (HFpEF) |
| Approval status | Investigational / off-label |
| Research papers | 5 |
Trulicity is not FDA-approved for heart failure (hfpef); the research below reflects investigational or off-label study only.
Research on dulaglutide for heart failure (hfpef) (5)
- Long-Term Activation of Glucagon-like peptide-1 receptor by Dulaglutide Prevents Diabetic Heart Failure and Metabolic Remodeling in Type 2 Diabetes.
- Comparative effectiveness of semaglutide <i>versus</i> liraglutide, dulaglutide or tirzepatide: a systematic review and meta-analysis.
- Comparative Effectiveness of Liraglutide and Dulaglutide in Heart Failure with Preserved Ejection Fraction: A Propensity Score-Matched Real-World Study.
- Cardiovascular Outcomes of Semaglutide vs Dulaglutide in Nonobese Type II Diabetes Patients With HFpEF.
- Tirzepatide versus dulaglutide in heart failure: another SURPASS attempt yielding a tie.